Denali Therapeutics (MUN:4DN) - Stock Price, News & Analysis

4DN Stock Overview

A biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. More details

4DN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 63.68% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Denali Therapeutics Inc. Competitors

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€882.0m

Heidelberg Pharma

XTRA:HPHA

€111.9m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.2b

Price History & Performance

Summary of all time highs, changes and price drops for Denali Therapeutics
Historical stock prices
Current Share Price	US$24.29
52 Week High	US$24.41
52 Week Low	US$15.47
Beta	1.39
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-47.67%
5 Year Change	48.84%
Change since IPO	42.38%

Recent updates

Shareholder Returns

	4DN	DE Biotechs	DE Market
7D	0%	1.2%	0.9%
1Y	n/a	-19.2%	7.7%

Return vs Industry: Insufficient data to determine how 4DN performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 4DN performed against the German Market.

Price Volatility

Is 4DN's price volatile compared to industry and market?
4DN volatility
4DN Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4DN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 4DN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	390	Ryan Watts	www.denalitherapeutics.com

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.

Denali Therapeutics Inc. Fundamentals Summary

How do Denali Therapeutics's earnings and revenue compare to its market cap?
4DN fundamental statistics
Market cap	€3.43b
Earnings (TTM)	-€405.05m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.5x

P/E Ratio

Is 4DN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4DN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$412.36m
Gross Profit	-US$412.36m
Other Expenses	US$15.14m
Earnings	-US$427.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.97
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 4DN perform over the long term?

See historical performance and comparison

4DN Stock Overview

Rewards

Risk Analysis

Denali Therapeutics Inc. Competitors

XTRA:BIO3

€1.3b

XTRA:FYB

€882.0m

XTRA:HPHA

€111.9m

XTRA:1SXP

€4.2b

Price History & Performance

Recent News & Updates

New major risk - Revenue size

Insufficient new directors

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

New minor risk - Insider selling

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

Insufficient new directors

Recent updates

New major risk - Revenue size

Insufficient new directors

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

New minor risk - Insider selling

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

Insufficient new directors

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

Insufficient new directors

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$1.06 loss per share (vs US$2.60 loss in FY 2022)

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Insufficient new directors

New major risk - Revenue and earnings growth

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Third quarter 2023 earnings released: US$0.72 loss per share (vs US$0.84 loss in 3Q 2022)

Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$1.34 (vs US$0.48 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.80 loss per share (vs US$0.53 loss in 1Q 2022)

Full year 2022 earnings released: US$2.60 loss per share (vs US$2.39 loss in FY 2021)

Co-Founder recently sold €247k worth of stock

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Co-Founder recently sold €136k worth of stock

Denali Therapeutics Announces DNL343 Interim Phase 1B Data in ALS and Entry into the Healey ALS Platform Trial

Third quarter 2022 earnings released: US$0.84 loss per share (vs US$0.69 loss in 3Q 2021)

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with Tak-594/Dnl593 (Ptv:Pgrn) and Progression to Enrolling Participants with Ftd-Grn

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome)

Insider recently sold €85k worth of stock

Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor in Parkinson's Disease

Denali Therapeutics Inc. Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

Denali Therapeutics Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold €615k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

Denali Therapeutics Inc. Announces U.S. Food and Drug Administration Clinical Hold on DNL919 Investigational New Drug (IND) Application

Co-Founder recently sold €198k worth of stock

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.54 loss in 3Q 2020)

Co-Founder recently sold €435k worth of stock

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

Insider recently sold €108k worth of stock

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$0.56 loss in 2Q 2020)

Director Jay Flatley sitting on 4 company boards

Director Jay Flatley sitting on 4 company boards

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.55 loss in 1Q 2020)

Denali Therapeutics Inc. Announces Final Results from Phase 1 and Phase 1B Studies of Its Small Molecule LRRK2 Inhibitor, BIIB122/DNL151

Denali Therapeutics Inc. Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

New 90-day low: €49.88

Full year 2020 earnings released: EPS US$0.65 (vs US$2.07 loss in FY 2019)

Co-Founder recently sold €549k worth of stock

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

Denali Therapeutics Inc. Appoints Nancy Thornberry to the Board of Directors

Denali Therapeutics Inc. Enters into A Settlement Agreement with A Stockholders to Resolve Lawsuit